Envista Holdings (NVST) Research & Development (2018 - 2026)
Envista Holdings (NVST) recorded quarterly Research & Development of $30.0 million in Q2 2026, down 6.54% quarter-over-quarter from $32.1 million in Q4 2025, and up 18.58% on a YoY basis from $25.3 million in Q2 2025.
Envista Holdings (NVST) Research & Development (2018 - 2026) Analysis & Trends
Envista Holdings' Research & Development history runs 9 years deep, the most recent figure standing at $30.0 million for Q2 2026.
- In Q2 2026, Research & Development rose 18.58% year-over-year to $30.0 million; the TTM figure through Apr 2026 stood at $118.7 million (up 17.41% YoY), while the FY2025 annual figure was $114.0 million, up 15.04% from the prior year.
- Research & Development was $30.0 million for Q2 2026 at Envista Holdings, down from $32.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $32.1 million in Q4 2025 to a low of $20.2 million in Q4 2023.
- Historically, Research & Development has averaged $25.7 million across 5 years, with a median of $25.3 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Research & Development decreased 17.89% in 2023, then soared 32.18% in 2024.
- A 5-year view of Research & Development shows it stood at $24.6 million in 2022, then declined by 17.89% to $20.2 million in 2023, then soared by 32.18% to $26.7 million in 2024, then grew by 20.22% to $32.1 million in 2025, then slipped by 6.54% to $30.0 million in 2026.
- The last three Research & Development figures came in at $30.0 million (Q2 2026), $32.1 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 147.79 Bn | 143.40 Bn | 1.83 Bn | 361.90 Mn |
| 2 | Becton Dickinson | 41.23 Bn | 40.22 Bn | 2.15 Bn | 249.00 Mn |
| 3 | Medline | 30.57 Bn | 36.41 Bn | 1.84 Bn | - |
| 4 | Resmed | 28.04 Bn | 26.38 Bn | 890.98 Mn | 94.27 Mn |
| 5 | West Pharmaceutical Services | 23.76 Bn | 23.24 Bn | 296.40 Mn | 15.80 Mn |
| 6 | Solventum | 13.40 Bn | 13.40 Bn | 1.10 Bn | 189.00 Mn |
| 7 | Cooper Companies | 13.18 Bn | 13.04 Bn | 735.40 Mn | 42.50 Mn |
| 8 | Align Technology | 12.72 Bn | 11.66 Bn | 736.59 Mn | 98.66 Mn |
| 9 | Baxter International | 10.71 Bn | 8.67 Bn | 891.00 Mn | 139.00 Mn |
| 10 | Envista Holdings | 4.04 Bn | 2.96 Bn | 390.10 Mn | 30.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 30.00 Mn |
| Dec 31, 2025 | 32.10 Mn |
| Sep 26, 2025 | 28.30 Mn |
| Jun 27, 2025 | 28.30 Mn |
| Mar 28, 2025 | 25.30 Mn |
| Dec 31, 2024 | 26.70 Mn |
| Sep 27, 2024 | 25.50 Mn |
| Jun 28, 2024 | 23.60 Mn |
| Mar 29, 2024 | 23.30 Mn |
| Dec 31, 2023 | 20.20 Mn |
| Sep 29, 2023 | 22.30 Mn |
| Jun 30, 2023 | 26.80 Mn |
| Mar 31, 2023 | 24.50 Mn |
| Dec 31, 2022 | 24.60 Mn |
| Sep 30, 2022 | 26.00 Mn |
| Jul 1, 2022 | 25.10 Mn |
| Apr 1, 2022 | 24.40 Mn |
| Dec 31, 2021 | 24.80 Mn |
| Oct 1, 2021 | 24.00 Mn |
| Jul 2, 2021 | 25.90 Mn |